688336 三生国健
交易中 02-05 09:30:20
资讯
新帖
简况
每周股票复盘:三生国健(688336)预计2025年净利29亿元
证券之星 · 02-01
每周股票复盘:三生国健(688336)预计2025年净利29亿元
1月27日三生国健涨10.93%,广发医疗保健股票A基金重仓该股
证券之星 · 01-27
1月27日三生国健涨10.93%,广发医疗保健股票A基金重仓该股
三生国健涨10.93%,开源证券二个月前给出“买入”评级
证券之星 · 01-27
三生国健涨10.93%,开源证券二个月前给出“买入”评级
三生国健(688336)披露2025年年度业绩预告,1月26日股价下跌2.54%
证券之星 · 01-26
三生国健(688336)披露2025年年度业绩预告,1月26日股价下跌2.54%
公告精选︱三生国健:2025年度预计净利润29.00亿元左右 同比涨幅约311.35%;东方日升:光伏产品未直接向商业航天卫星公司供货
格隆汇 · 01-26
公告精选︱三生国健:2025年度预计净利润29.00亿元左右 同比涨幅约311.35%;东方日升:光伏产品未直接向商业航天卫星公司供货
三生国健(688336.SH)发预增,预计2025年度归母净利润29亿元左右 同比增长311.35%
智通财经 · 01-26
三生国健(688336.SH)发预增,预计2025年度归母净利润29亿元左右 同比增长311.35%
三生国健(688336)披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果公告,1月19日股价下跌1.49%
证券之星 · 01-19
三生国健(688336)披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果公告,1月19日股价下跌1.49%
蓄势、崛起:从三生国健(688336.SH)看中国创新药企的下一站
格隆汇 · 01-19
蓄势、崛起:从三生国健(688336.SH)看中国创新药企的下一站
每周股票复盘:三生国健(688336)限制性股票归属130万股
证券之星 · 01-18
每周股票复盘:三生国健(688336)限制性股票归属130万股
1月12日三生国健跌6.25%,交银医药创新股票A基金重仓该股
证券之星 · 01-12
1月12日三生国健跌6.25%,交银医药创新股票A基金重仓该股
光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事
12月15日三生国健跌5.83%,交银医药创新股票A基金重仓该股
证券之星 · 2025-12-15
12月15日三生国健跌5.83%,交银医药创新股票A基金重仓该股
三生国健(688336)披露关于收到实际控制人《解除<一致行动协议>的通知函》的提示性公告,12月12日股价上涨3.48%
证券之星 · 2025-12-12
三生国健(688336)披露关于收到实际控制人《解除<一致行动协议>的通知函》的提示性公告,12月12日股价上涨3.48%
11月27日三生国健跌5.40%,交银医药创新股票A基金重仓该股
证券之星 · 2025-11-27
11月27日三生国健跌5.40%,交银医药创新股票A基金重仓该股
每周股票复盘:三生国健(688336)股东拟减持不超1.00%股份
证券之星 · 2025-11-16
每周股票复盘:三生国健(688336)股东拟减持不超1.00%股份
三生国健(688336)披露股东减持股份计划公告,11月10日股价下跌0.35%
证券之星 · 2025-11-10
三生国健(688336)披露股东减持股份计划公告,11月10日股价下跌0.35%
三生国健(688336.SH):达佳国际拟减持不超1%股份
智通财经 · 2025-11-09
三生国健(688336.SH):达佳国际拟减持不超1%股份
每周股票复盘:XD三生国(688336)三生国健股价异动因涨幅偏离值超30%
证券之星 · 2025-11-09
每周股票复盘:XD三生国(688336)三生国健股价异动因涨幅偏离值超30%
三生国健(688336.SH):辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性
智通财经 · 2025-11-03
三生国健(688336.SH):辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性
股市必读:三生国健10月31日涨停收盘,收盘价72.96元
证券之星 · 2025-11-03
股市必读:三生国健10月31日涨停收盘,收盘价72.96元
加载更多
公司概况
公司名称:
三生国健药业(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-22
主营业务:
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。
发行价格:
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":58.88,"timestamp":1770255020000,"preClose":59.15,"halted":0,"volume":24729,"delay":0,"changeRate":-0.0046,"floatShares":617000000,"shares":618000000,"eps":1.4083,"marketStatus":"交易中","change":-0.27,"latestTime":"02-05 09:30:20","open":58.3,"high":58.88,"low":58.3,"amount":1443600,"amplitude":0.0098,"askPrice":58.88,"askSize":6,"bidPrice":58.79,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.4083,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770262200000},"marketStatusCode":2,"adr":0,"adjPreClose":59.15,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770255000000,1770262200000],[1770267600000,1770274800000]],"highLimit":65.07,"lowLimit":53.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":618086503,"isCdr":false,"pbRate":6.2,"roa":"--","peRate":41.809274,"roe":"6.95%","epsLYR":1.14,"committee":0.578947,"marketValue":36393000000,"turnoverRate":0,"status":1,"floatMarketCap":36316000000},"requestUrl":"/m/hq/s/688336","defaultTab":"news","newsList":[{"id":"2608077487","title":"每周股票复盘:三生国健(688336)预计2025年净利29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077487","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077487?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:07","pubTimestamp":1769886430,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,三生国健报收于60.22元,较上周的58.76元上涨2.48%。本周,三生国健1月27日盘中最高价报66.28元。公司公告汇总:因收到707项目授权许可首付款,确认收入约28.90亿元人民币。三生国健发布业绩预告,预计2025年全年归属净利润盈利约29亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2606436201","title":"1月27日三生国健涨10.93%,广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606436201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606436201?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:35","pubTimestamp":1769502927,"startTime":"0","endTime":"0","summary":"证券之星消息,1月27日三生国健涨10.93%,收盘报63.53元,换手率3.27%,成交量20.14万手,成交额12.7亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共22家,其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为40.74亿元,最新净值1.8427,较上一交易日下跌0.6%,近一年上涨16.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2606201428","title":"三生国健涨10.93%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606201428?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:35","pubTimestamp":1769502921,"startTime":"0","endTime":"0","summary":"今日三生国健涨10.93%,收盘报63.53元。2025年10月28日,开源证券研究员余汝意,余克清,汪晋发布了对三生国健的研报《公司信息更新报告:业绩同环比增速稳健,在研项目稳步推进》,该研报对三生国健给出“买入”评级。研报中预计2025-2027年归母净利润为4.64/5.43/6.81亿元,EPS为0.75/0.88/1.1元,当前股价对应PE为79.7/68.1/54.4倍,考虑公司自免新产品即将上市,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为59.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700027002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","161027"],"gpt_icon":0},{"id":"2606998249","title":"三生国健(688336)披露2025年年度业绩预告,1月26日股价下跌2.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606998249","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606998249?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:49","pubTimestamp":1769438946,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘,三生国健报收于57.27元,较前一交易日下跌2.54%,最新总市值为353.98亿元。该股当日开盘58.62元,最高58.98元,最低56.88元,成交额达1.92亿元,换手率为0.54%。近日,三生国健药业(上海)股份有限公司发布2025年年度业绩预告。本次业绩预告未经注册会计师审计,最终数据以正式披露的2025年年报为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2606324376","title":"公告精选︱三生国健:2025年度预计净利润29.00亿元左右 同比涨幅约311.35%;东方日升:光伏产品未直接向商业航天卫星公司供货","url":"https://stock-news.laohu8.com/highlight/detail?id=2606324376","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606324376?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:37","pubTimestamp":1769434639,"startTime":"0","endTime":"0","summary":"特宝生物:拟发行可转债募资不超15.33亿元","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3678501","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["300118","688336"],"gpt_icon":0},{"id":"2606121502","title":"三生国健(688336.SH)发预增,预计2025年度归母净利润29亿元左右 同比增长311.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606121502","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606121502?lang=zh_cn&edition=full","pubTime":"2026-01-26 19:49","pubTimestamp":1769428191,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健 发布2025年年度业绩预告,公司2025年度预计实现归属于母公司所有者的净利润29亿元左右,与上年同期相比,将增加21.95亿元左右,相比上年同期涨幅约311.35%。报告期内,公司与辉瑞公司达成重要合作;公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元人民币,导致2025年度的营业收入、归属于母公司所有者的净利润以及扣除非经常损益后归属于母公司所有者的净利润均出现较大幅度的增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"三生国健(688336.SH)发预增,预计2025年度归母净利润29亿元左右 同比增长311.35%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688336"],"gpt_icon":0},{"id":"2604184442","title":"三生国健(688336)披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果公告,1月19日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604184442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604184442?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:33","pubTimestamp":1768815236,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘,三生国健报收于58.0元,较前一交易日下跌1.49%,最新总市值为358.49亿元。该股当日开盘58.62元,最高59.0元,最低57.69元,成交额达1.64亿元,换手率为0.46%。公司近日发布公告称,三生国健药业(上海)股份有限公司已完成2024年限制性股票激励计划首次授予部分第一个归属期的股份登记。归属股份已于2026年1月15日完成登记,限售期为6个月,尚未上市流通。本次变动后,公司总股本由616,785,793股增至618,086,503股,未导致公司控制权发生变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900023706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2604333906","title":"蓄势、崛起:从三生国健(688336.SH)看中国创新药企的下一站","url":"https://stock-news.laohu8.com/highlight/detail?id=2604333906","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604333906?lang=zh_cn&edition=full","pubTime":"2026-01-19 09:55","pubTimestamp":1768787704,"startTime":"0","endTime":"0","summary":"作为中国创新药企的代表,三生国健在穿越行业周期后,逐步实现了从蓄势到崛起的关键转变。站在新起点,随着更多产品陆续落地和价值兑现,公司有望持续释放增长潜力,迎来更加广阔的发展空间。","market":"hk","thumbnail":"https://img2.gelonghui.com/b17e2-55ddaedc-be70-4f15-b20a-c9c57f8e6a27.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-55ddaedc-be70-4f15-b20a-c9c57f8e6a27.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3609994","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","BK1574","BK1161","BK0239","688336","159992"],"gpt_icon":0},{"id":"2604923918","title":"每周股票复盘:三生国健(688336)限制性股票归属130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923918?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:49","pubTimestamp":1768675747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,三生国健报收于58.88元,较上周的63.8元下跌7.71%。本周,三生国健1月12日盘中最高价报63.77元。三生国健当前最新总市值363.16亿元,在生物制品板块市值排名8/51,在两市A股市值排名569/5183。本周关注点公司公告汇总:三生国健完成2024年限制性股票激励计划首次授予部分第一个归属期股份登记,归属数量为1,300,710股。本次归属股份已于2026年1月15日完成登记,限售期为6个月,尚未上市流通。公司总股本由616,785,793股增至618,086,503股,未导致控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2602591237","title":"1月12日三生国健跌6.25%,交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602591237","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602591237?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:38","pubTimestamp":1768203485,"startTime":"0","endTime":"0","summary":"证券之星消息,1月12日三生国健跌6.25%,收盘报59.81元,换手率1.51%,成交量9.32万手,成交额5.6亿元。重仓三生国健的前十大公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级4家,增持评级2家;过去90天内机构目标均价为75.26。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200015073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1161","BK0239","BK1515","BK1574","688336"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易,但从三季度以来,原本利好的消息却不被二级市场买账。最近一周,BD交易再掀一个小高潮。12月22日,先声药业(02096.HK)宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","01801","BK0196","02142","688331","LU0502904849.HKD","01530","LU0405327148.USD","LU2580892862.HKD","01167","BK0028","600276","000661","BK0057","BK1593","BK0012","LU1328615791.USD","LU1997245094.SGD","LU1969619763.USD","LU2495084118.USD","BK1589","603087","02096","BK0183","BK0239","LU1146622755.USD","02509","BK0188","688062","002755","06978","LU1064131003.USD","LU2097828474.EUR","688336","LU2097828557.USD","09995","LU1997245177.USD","LU1064130708.USD","LU2097828805.USD","LU0405327494.USD","BK0060","LU1781817850.SGD","LU2097828631.EUR","BK1574","LU2488822045.USD","LU2097828714.EUR","LU1997244956.HKD","BK1161","03692","688428"],"gpt_icon":0},{"id":"2591861598","title":"12月15日三生国健跌5.83%,交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591861598","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591861598?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:35","pubTimestamp":1765784122,"startTime":"0","endTime":"0","summary":"证券之星消息,12月15日三生国健跌5.83%,收盘报60.7元,换手率0.85%,成交量5.24万手,成交额3.22亿元。重仓三生国健的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级4家,增持评级3家;过去90天内机构目标均价为70.27。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1161","BK0239","BK1515","BK1574","688336"],"gpt_icon":0},{"id":"2590727265","title":"三生国健(688336)披露关于收到实际控制人《解除<一致行动协议>的通知函》的提示性公告,12月12日股价上涨3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590727265","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590727265?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:52","pubTimestamp":1765533153,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘,三生国健报收于64.46元,较前一交易日上涨3.48%,最新总市值为397.58亿元。同日,三生国健发布公告称,公司收到实际控制人LOU JING出具的《解除<一致行动协议>的通知函》。根据公告内容,LOU JING与TAN BO、苏冬梅、黄斌签署的《一致行动协议》自签署通知函之日起解除。LOU JING通过三生制药及其下属企业和香港达佳合计控制公司84.96%股份的表决权,可支配的表决权比例未发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200028638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2586217581","title":"11月27日三生国健跌5.40%,交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586217581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586217581?lang=zh_cn&edition=full","pubTime":"2025-11-27 15:33","pubTimestamp":1764228808,"startTime":"0","endTime":"0","summary":"证券之星消息,11月27日三生国健跌5.40%,收盘报64.7元,换手率0.98%,成交量6.04万手,成交额4.0亿元。重仓三生国健的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级4家,增持评级3家;过去90天内机构目标均价为66.63。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700017113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","688336","BK1161","BK0239","09939","BK1515"],"gpt_icon":0},{"id":"2583593966","title":"每周股票复盘:三生国健(688336)股东拟减持不超1.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593966","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583593966?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:56","pubTimestamp":1763229370,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,三生国健报收于72.37元,较上周的65.23元上涨10.95%。本周,三生国健11月14日盘中最高价报77.26元。达佳国际拟在2025年12月1日至2026年2月28日期间,通过集中竞价方式减持不超过6,167,857股,即不超过公司总股本的1.00%,减持原因为自身资金需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2582299788","title":"三生国健(688336)披露股东减持股份计划公告,11月10日股价下跌0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582299788","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582299788?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:22","pubTimestamp":1762766555,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘,三生国健报收于65.0元,较前一交易日下跌0.35%,最新总市值为400.91亿元。公司近日发布公告称,截至公告披露日,达佳国际(香港)有限公司持有三生国健股份25,160,657股,占总股本的4.08%。达佳国际拟在2025年12月1日至2026年2月28日期间,通过集中竞价方式减持不超过6,167,857股,即不超过公司总股本的1.00%,减持原因为自身资金需求。本次减持计划不会导致公司控制权变更,且符合相关法律法规及承诺要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2582932896","title":"三生国健(688336.SH):达佳国际拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582932896","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582932896?lang=zh_cn&edition=full","pubTime":"2025-11-09 15:35","pubTimestamp":1762673715,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健(688336.SH)发布公告,根据股东自身资金需求,达佳国际拟在本次减持计划公告之日起15个交易日后的三个月内,以集中竞价方式择机减持其所持公司股份合计不超过616.79万股,即不超过公司总股本的1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2582668768","title":"每周股票复盘:XD三生国(688336)三生国健股价异动因涨幅偏离值超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582668768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582668768?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:15","pubTimestamp":1762622112,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,XD三生国报收于65.23元,较上周的72.96元下跌10.59%。本周,XD三生国11月3日盘中最高价报83.0元,股价触及近一年最高点。本周关注点来自交易信息汇总:三生国健因连续3个交易日涨幅偏离值累计达30%两度登上龙虎榜。来自公司公告汇总:三生国健股票交易连续两个交易日涨幅偏离值累计超过30%,构成异常波动。公司董事、高管及控股股东在异常波动期间未买卖公司股票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2580966482","title":"三生国健(688336.SH):辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2580966482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580966482?lang=zh_cn&edition=full","pubTime":"2025-11-03 18:25","pubTimestamp":1762165505,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健 发布股价异动公告称,公司及三生制药和沈阳三生共同授予被许可方辉瑞公司在许可区域及领域的独家开发、生产和商业化许可产品707项目的权利。《许可协议》于2025年7月24日正式生效。2025年10月30日,辉瑞在ClinicalTrials.gov网站上登记了PD-1/VEGF双抗PF-08634404的两项全球III期临床试验。鉴于《许可协议》中所约定的里程碑付款需要满足一系列特定条件,其最终付款尚存在不确定性,敬请广大投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023059063.AUD","SGXZ57979304.SGD","BK4134","IE00B19Z3B42.SGD","LU0122379950.USD","LU0306806265.USD","LU0289739699.SGD","BK4023","LU0456855351.SGD","SG9999001176.USD","BK4533","LU1057294990.SGD","SG9999003800.SGD","BK4585","BK0239","LU0058720904.USD","LU0868494617.USD","III","LU1883839398.USD","SG9999002224.SGD","LU0225771236.USD","IE00BLSP4239.USD","LU1169589451.USD","LU0985481810.HKD","LU1169590202.USD","IE000M9KFDE8.USD","LU1894683264.USD","LU1066053197.SGD","LU0306807586.USD","SG9999001176.SGD","BK4581","SG9999002232.USD","BK4550","LU0234572021.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","PD","688336","LU1894683348.USD","SG9999013999.USD","BK4534","BK4568","LU0321505868.SGD","BK4592","LU0170899867.USD","BK4007","LU1066051498.USD","LU0225284248.USD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2580428707","title":"股市必读:三生国健10月31日涨停收盘,收盘价72.96元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580428707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580428707?lang=zh_cn&edition=full","pubTime":"2025-11-03 00:49","pubTimestamp":1762102152,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,三生国健报收于72.96元,上涨20.0%,涨停,换手率1.87%,成交量11.52万手,成交额7.99亿元。来自公司公告汇总:三生国健公布2025年半年度权益分派方案,每股派发现金红利0.033元(含税),股权登记日为2025年11月6日。交易信息汇总三生国健10月31日涨停收盘,收盘价72.96元。该股于10点30分涨停,1次打开涨停,截至收盘封单资金为285.51万元,占其流通市值0.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300000191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770255028782,"stockEarnings":[{"period":"1week","weight":-0.0587},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.1448},{"period":"6month","weight":0.1936},{"period":"1year","weight":1.6495},{"period":"ytd","weight":-0.0071}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11202人(较上一季度减少12.77%)","perCapita":"55060股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"61808万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}